A Phase 1 Multi-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral IMB-1018972 (IMB-101) in Healthy Volunteers (HV)
Latest Information Update: 24 May 2021
At a glance
- Drugs Ninerafaxstat (Primary) ; Trimetazidine
- Indications Angina pectoris; Diabetic cardiomyopathy; Heart failure; Hypertrophic cardiomyopathy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Imbria Pharmaceuticals
- 24 May 2021 New trial record
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology
- 17 May 2021 According to an Imbria Pharmaceuticals media release, data from this study was featured in presentations at The American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21).